BASi Names John E. Sagartz Chief Strategy Officer
November 01 2018 - 8:43AM
Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the
“Company”) today announced the appointment of John E. Sagartz, DVM,
PhD, DACVP, as the Company’s Chief Strategy Officer.
Dr. Sagartz founded and led Seventh Wave Laboratories for over
fifteen years prior to BASi’s acquisition of its operations in July
of this year. Following the acquisition, Dr. Sagartz joined BASi’s
Board of Directors to help guide operations in order to provide
broader solutions and greater scientific expertise to the Company’s
clients. As Chief Strategy Officer, Dr. Sagartz will help define
and accelerate the next phase of growth for the Company.
“John is an outstanding scientist, entrepreneur, and visionary,
and I’m excited to have him in this role,” said Dr. Gregory C.
Davis, BASi’s Chairman of the Board. “His depth and strength of
leadership will be invaluable as our Company grows in the coming
months and years. John’s guidance will drive our strategy of
delivering operational and service excellence, maximizing our core
competencies, and building strategic relationships to facilitate
the success of our clients and partners.”
Dr. Sagartz began his career as a toxicologic pathologist at
Searle/Monsanto in 1996, and held positions of increasing
responsibility as section head, director, preclinical development
site head, and fellow, following Monsanto’s merger with Pharmacia.
After Pfizer’s acquisition of Pharmacia in 2003, Dr. Sagartz
founded Seventh Wave Laboratories where he served as President and
Chief Executive Officer, and Chief Strategy Officer.
Dr. Sagartz is an adjunct associate professor of Comparative
Medicine at St. Louis University’s College of Medicine and serves
on the Board of Directors of the Missouri Biotechnology
Association. He received his Bachelor of Science and Doctor of
Veterinary Medicine degrees from Kansas State University and, after
completing residency training in anatomic pathology, earned his
Doctor of Philosophy from The Ohio State University.
“Joining with BASi has allowed us to be more strategic in
helping clients realize their goals, yet still be of a size to
provide personalized service,” said Dr. Sagartz. “As a combined
force, we’re seizing the opportunity to strengthen our offerings
and create even more value for our clients. We have a great
leadership team and I’m excited guide to our strategies as we
continue to grow.”
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract
research services and monitoring instruments to emerging
pharmaceutical companies and the world's leading drug development
companies and medical research organizations. The Company focuses
on developing innovative services supporting its clients’ discovery
and development objectives for improved decision-making and
accelerated goal attainment. BASi products focus on increasing
efficiency, improving data, and reducing the cost of taking new
drugs to market. Visit www.BASinc.com for more
information about BASi.
This release may contain forward-looking statements that are
subject to risks and uncertainties including, but not limited to,
risks and uncertainties related to changes in the market and demand
for our products and services, the development, marketing and sales
of products and services, changes in technology, industry and
regulatory standards, and various market and operating risks
detailed in the company's filings with the U.S. Securities and
Exchange Commission.
Company Contact:Jill C.
BlumhoffChief Financial OfficerPhone:
756.497.8381jblumhoff@BASinc.com
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/76871562-2a53-427d-9a58-4a86ca364c21
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Apr 2023 to Apr 2024